Strategic Merger Opportunity G1 Therapeutics is in a merger deal with Pharmacosmos that could lead to accelerated commercialization, expanded product access, and potential channel integration. This suggests a priority for partnership discussions that align commercial routes, distribution, and post-merger go-to-market planning.

Oncology Market Expansion Recent COSELA launch for small cell lung cancer positions G1 as a commercial-stage oncology company with myeloprotection offerings. There is potential to sell complementary supportive care tools, diagnostic services, or additional myeloprotection solutions to oncology clinics and treatment centers.

Licensing Prospects A licensing deal with Pepper Bio indicates openness to strategic partnerships and milestone-driven collaborations. Engage in conversations around co-development, regional licensing, or milestone-based revenue sharing to unlock near-term monetization.

Capital Market Activity Historically active in fundraising and public markets, with a recent $697M funding backdrop and public listing. This signals readiness for partnership financing opportunities, joint ventures, or strategic equity arrangements to support expansion or pipeline advancement.

Operational Readiness A mid-sized biotech with a broad tech stack (SAS, AWS, SAP, etc.) and a formal executive team structure (Head of Corporate Legal), suggesting readiness for enterprise-grade collaboration, data-sharing agreements, and compliant, scalable partner integrations.